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doi:10.1016/j.jtcvs.2008.02.040Background: Early survival for children with single-ventricle congenital heart disease
has improved, but late attrition remains a serious problem. The endothelin-1 G5665T
single nucleotide polymorphism has been linked to increased vascular reactivity and
hypertension. The goal of this study was to determine whether this single nucleotide
polymorphism alters transplant-free survival for children with single-ventricle
congenital heart disease.
Methods: DNA was isolated from 165 children with single-ventricle congenital heart
disease born between January 1980 and December 2006. The endothelin-1 G5665T
single nucleotide polymorphism genotype was determined by using real-time poly-
merase chain reaction. Kaplan–Meier survival curves were generated with a combined
end point of death or transplantation. The Cox proportional hazard method was used
to evaluate potential covariates.
Results: The endothelin-1 G5665T genotype was significantly associated with trans-
plant-free survival for the group as a whole (P5 .002), with the greatest effect in chil-
dren with hypoplastic left heart syndrome (n5 64, P5 .0002) as opposed to patients
with other types of single-ventricle anatomy (n5 101, P5 .1). Cox proportional haz-
ard modeling revealed 3 independent predictors of poor outcome: endothelin G5665T
genotype (T/T genotype, P 5 .001), prematurity (gestational age ,37 weeks, P 5
.02), and era of surgical intervention (1990s vs other decades, P 5 .02).
Conclusions: Long-term survival of single-ventricle patients is dependent on many
factors. These data suggest that genetic variability involving vascular resistance mod-
ifiers, such as endothelin-1, might play an important role, particularly in patients with
hypoplastic left heart syndrome. Future studies should include evaluation of the
relationship between endothelin genotype and plasma endothelin levels and possibly
therapeutic trials of endothelin blockers in high-risk patients.
T
he majority of children born with single-ventricle congenital heart disease
(SV-CHD) undergo staged palliation culminating in the Fontan procedure dur-
ing early childhood. Although the early survival of these children has steadily
improved over the past decades, midterm to long-term attrition remains a significant
concern. Failure of single-ventricle palliation is clearly multifactorial, as has been
demonstrated by several large cross-sectional studies investigating the potential ana-
tomic and treatment-related causes of Fontan failure.1,2 Although these studies have
identified risk factors for early Fontan failure, such as younger age at surgical inter-
vention, increased pulmonary artery pressures, heterotaxy syndrome, and longer car-
diopulmonary bypass time, the results have been inconsistent and, to quote Gentles
and colleagues,1 ‘‘A continuing late hazard phase is associated with few patient-
related variables and does not appear related to procedural variables.’’ Although there
is ample evidence that genetic factors can play a significant role in the development of
cardiovascular disease and response to therapy in adults,3-6 there have been no studies
reported regarding the effect of genetic factors on outcomes for single-ventricle
patients.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 1 117
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DAbbreviations and Acronyms
ET-1 5 Endothelin-1
HLHS 5 Hypoplastic left heart syndrome
SNP 5 Single nucleotide polymorphism
SV-CHD 5 Single-ventricle congenital heart disease
Considering the demonstrated sensitivity of single-ventri-
cle patients to increased pulmonary vascular resistance and
the potential for late single-ventricle dysfunction in the face
of increased systemic vascular resistance, one area of partic-
ular interest for this patient population is vasomotor control.
Endothelin-1 (ET-1) is one of the most potent endogenous
vasoconstrictors known. A single nucleotide polymorphism
(SNP) in the preproendothelin-1 gene involving a G-to-T re-
placement at nucleotide 5665 in exon 5 (rs5370; correspond-
ing to a Lys/Asn change at codon 198) has been studied in
several adult patient populations. The T allele (Asn198) is as-
sociated with increased vascular reactivity in human thoracic
artery specimens in vitro,7 hypertension in obese popula-
tions,8 heart failure,9 and malignant arrhythmias in adults
with structural cardiac disease.10
The goal of the present study was to determine whether the
ET-1 G5665T polymorphism has any effect on midterm out-
come for palliated single-ventricle patients. Our hypothesis
was that children who are homozygous for the T allele would
be at increased risk for midterm to late-term failure of single-
ventricle palliation compared with the more common G allele
homozygotes and heterozygotes.
Materials and Methods
Emory University and Children’s Healthcare of Atlanta Institutional
Review Board approval was granted for this study. Informed con-
sent was obtained from the patients’ legal guardians, with patient
assent obtained for children older than 6 years.
Patient Population
All patients born with SV-CHD presenting to Children’s Healthcare
of Atlanta, Egleston Hospital, between July 2004 and February 2007
were considered for enrollment in the study. The patient population
included 2 discrete groups: (1) children who are currently undergo-
ing staged palliation or who have completed staged palliation with
a Fontan procedure and (2) patients with SV-CHD in whom sin-
gle-ventricle palliation has previously failed and who underwent
cardiac transplantation in the past. Patients at the first stage of palli-
ation were enrolled before transfer out of the intensive care unit so as
to eliminate first-stage operative mortality from this analysis of mid-
term to long-term outcomes. For patients who previously underwent
transplantation, the date of transplantation was considered their end
point. Those who underwent elective transplantation as infants with-
out attempted staged palliation were excluded from the study
because their genetic milieu could not be considered a contributor
to the ‘‘failure’’ of single-ventricle palliation.118 The Journal of Thoracic and Cardiovascular Surgery c JulyOne hundred sixty-five patients were enrolled of 192 evaluated
for the study. Patients were not enrolled for the following reasons:
11 parents either refused consent or could not be contacted, 8
were non-English speaking and adequate translation could not be ar-
ranged for informed consent, and 8 had elective neonatal heart trans-
plantations without attempted staged palliation.
DNA Isolation and Genotyping
After obtaining informed consent, a 5-mL aliquot of whole blood
was drawn during routine cardiac catheterization, during anesthe-
sia induction for cardiac surgery, or from an arterial catheter in
the postoperative period at least 24 hours after any exogenous
blood exposure. Genomic DNA was isolated by using standard
techniques (Puregene; Gentra Systems, Minneapolis, Minn). The
ET-1 G5665T polymorphism was genotyped by using an Applied
Biosystems Taqman 7000 analyzer (Foster City, Calif). The
primers and probes used are shown in Table 1.
Follow-up
The parents/guardians of the patients have been contacted by tele-
phone every 6 months for serial follow-up. Failure of single-ventri-
cle palliation was defined as listing for cardiac transplantation or
death. Patients who had cardiac transplantations before enrollment
were assigned an end point date corresponding to the date of the
transplantation and were not contacted beyond the date of enroll-
ment.
Statistical Analysis
Data are presented as means6 standard deviations. Categorical var-
iables were compared by using c2 analysis or the Fisher exact test, as
appropriate. Continuous variables were compared by using the
Kruskal–Wallis test.
Time to failure of single-ventricle palliation was calculated from
the date of birth to the date of death or listing for cardiac transplan-
tation. Transplant-free survival curves were calculated by using the
Kaplan–Meier method and compared with the log rank test. The Cox
proportional hazard model method was used to evaluate the joint
effect of the studied polymorphism and potential covariates. A back-
ward elimination multiple regression was used. At each step of
model fitting, the Wald test was used to eliminate variables until
all remaining variables had a P value of less than or equal to .05.
All P values were 2-sided.
Results
Of the 165 patients enrolled, there were 109 male and 56
female patients. Birthweight was 3.2 6 0.6 kg (reliable
data available for 161 patients). Cardiac anatomy at birth is
summarized in Table 2. The group labeled ‘‘other single-
ventricle physiology’’ included a wide variety of anatomies,
including double-outlet right ventricle variants with hypo-
plastic or atretic mitral valves, ‘‘upstairs/downstairs’’ ventri-
cles with straddling atrioventricular valves, and others that
did not fit the broader categories. A genetic syndrome was
identified in 9 (5%) of 165 patients, including 4 with
Down syndrome, 2 with Turner’s mosaic, and 1 each with
DiGeorge syndrome, Klinefelter syndrome, and sickle cell
anemia. Other patient demographics and characteristics are2008
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notype. For surviving patients who have not had a heart
transplantation (those who were censored), the mean fol-
low-up time was 4.36 4.1 years (range, 125 days–22 years).
The stage of palliation or end point achieved as of the last
follow-up for the group as a whole is shown in Table 4.
Kaplan–Meier survival analysis demonstrates that the ET-
1 G5665T polymorphism is significantly associated with
transplant-free survival (P 5 .002; Figure 1, A). Median
actuarial survivals were 5, 17, and 25 years for the T/T
(n5 10), G/G (n5 103), and G/T (n5 52) genotypes, respec-
tively. Using a recessive gene model in which the T/T group
is compared against the other 2 groups (G/G 1 G/T) yields
a stronger association with outcome (P5 .001; Figure 1, B).
It is interesting to note that the observed effect of this poly-
morphism derives primarily from a transplant-free survival
decrement in the subgroup of patients with hypoplastic left
heart syndrome (HLHS) who have the T/T genotype (Fig-
ure 2). Kaplan–Meier analysis of patients with HLHS dem-
onstrates a significant association between ET-1 G5665T
genotype and survival (n 5 64, P 5 .0002), as opposed to
the single-ventricle patients with other cardiac anatomies,
for whom there is not a significant association (n 5 101,
P5 .12). HLHS diagnosis in and of itself did not affect survival
when compared against other diagnoses (P5 .76, Figure 3).
Cox proportional hazard analysis was performed, includ-
ing the following variables: cardiac anatomy, single-ventricle
morphology (right vs left ventricle), genetic syndromes,
TABLE 1. Primers and probes used to genotype the
endothelin-1 G5665T polymorphism
Primer/probe Sequence
Forward ACCATGAGAAACAGCGTCAAATCA
Reverse GTGGGTCACATAACGCTCTCT
Vic AGGCAAGCCCTCC
Fam AAAGGCAATCCCTCC
Vic and Fam are Fluorescent Taqman reporter dyes (Applied Biosystems,
Foster City, Calif).
TABLE 2. Cardiac anatomy at birth
Cardiac anatomy G/G G/T T/T No. (%)
Hypoplastic left heart syndrome 38 20 6 64 (39)
Hypoplastic RV with pulmonary
or tricuspid atresia
9 6 2 35 (21)
Double-inlet left ventricle 24 11 0 17 (10)
Unbalanced atrioventricular
canal defect
6 3 0 9 (5)
Heterotaxy syndrome 4 5 1 10 (6)
Other single-ventricle physiology 22 7 1 30 (18)
Total 103 52 10 165 (100)
RV, Right ventricle.The Journal of Thorbirthweight, gestational age, era (grouped by birth date:
1980–1989, 1990–1999, and 2000–2006), ethnicity, sex,
and ET-1 G5665T recessive model (T/T genotype vs
‘‘other’’). This analysis produced a model with 3 significant
independent predictors of transplant-free survival: ET-1 ge-
notype (T/T vs ‘‘other’’), prematurity, and era of birth (P 5
.001, .02, and .02, respectively). The higher-risk groups for
these variables were T/T genotype, prematurity (,37 weeks’
gestational age), and birth date in the 1990s as opposed to the
1980s or 2000s. The distributions of genotypes across these
variables are shown in Tables 2 and 3.
Discussion
Although the early survival for children with SV-CHD has
improved dramatically over the past 2 decades, late attrition
remains a significant concern. Gentles and colleagues1 re-
viewed the long-term results of 500 children who had Fontan
TABLE 3. Patient characteristics for endothelin-1 G5665T
genotype groups
G/G G/T T/T P value
Sex (% male) 63 75 50 .18
Race
White 58 40 7
African-American 29 6 1
Hispanic 11 3 2
Other 5 3 0 .30
Birthweight (kg) 3.2 6 0.5 3.2 6 0.6 3.1 6 0.4 .97
Premature (%) 18 10 0 .45
Ventricular
morphology (% LV)
37 44 20 .33
Genetic syndromes (%) 8 19 0 .23
Era (birth date)
1980–1989 6 2 2
1990–1999 20 11 2
2000–2007 77 39 6 .42
Prematurity was defined as gestational age of less than 37 weeks.
LV, Left ventricle.
TABLE 4. Palliation stage completed or end point as of last
follow-up
Palliation stage or end point No. (%)
Stage 1 (eg, BT shunt, PA band, or Norwood
procedure)
5 (3)
Stage 2 (Glenn shunt or hemi-Fontan procedure) 42 (25)
Fontan procedure 85 (52)
Listed for transplantation or having undergone
transplantation
21 (13)
Died 12 (7)
Total 165 (100)
BT, Blalock–Taussig; PA, pulmonary artery.acic and Cardiovascular Surgery c Volume 136, Number 1 119
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hazard phase of staged single-ventricle palliation by includ-
ing only patients undergoing Fontan completion, the actuar-
ial transplant-free survival at 10 years was approximately
71%. Also, given the time period during which these patients
Figure 1. A, Transplant-free actuarial survival for all single-
ventricle patients stratified by endothelin-1 G5665T polymorphism
genotype (P 5 .002). B, Transplant-free actuarial survival for all
single-ventricle patients using a recessive model for endothe-
lin-1 G5665T polymorphism (T/T genotype vs G/T and G/G geno-
types combined, P 5 .001). ET1, Endothelin-1.120 The Journal of Thoracic and Cardiovascular Surgery c Julyunderwent palliation, the longest follow-up groups were
composed of relatively less complicated anatomic groups,
such as patients with morphologic left ventricles and nor-
mally related great vessels. Although the outcomes for pa-
tients from more recent years might be better due to earlier
staging and improvements in surgical and medical manage-
ment, the increasing survival and progression through pallia-
tion of the more complicated single-ventricle variants, such
as HLHS, might well offset any improvement in outcomes
for the group as a whole. As such, investigations into the
causes of late Fontan failure are vitally important.
Unfortunately, the results of the larger follow-up studies
evaluating anatomic and perioperative risk factors for early
and late Fontan failure have been inconsistent and incom-
plete. Although Gentles and colleagues1 found that cardiac
anatomy was a significant predictor of late Fontan failure
with complex variants, such as HLHS and heterotaxy syn-
drome, faring worse, Mitchell and associates2 found no asso-
ciation between anatomy and midterm outcome. In general,
the causes of midterm to long-term Fontan failure have not
been identified.
The ET-1 G5665T SNP has been linked to increased vas-
cular reactivity and several cardiovascular disorders in
adults.7-10 ET-1 is well known as a powerful vasoconstrictive
agent that has long-lasting effects after nearly irreversible
binding to its receptor. However, another mechanism of
action has been identified at ET-1 concentrations that are
physiologically relevant. At subthreshold concentrations
(10–100 pmol/L), ET-1 has little or no direct effect on iso-
lated vascular rings from rabbit aortas or human internal tho-
racic arteries.7,11 However, this concentration range of ET-1,
which is comparable with circulating levels, does result in po-
tentiation of catecholamine-induced vasoconstriction by low
concentrations of norepinephrine or phenylephrine. Henrion
and Laher11 demonstrated that this effect is endothelium in-
dependent and does not result from changes in calcium flux.
Iglarz and coworkers7 demonstrated that the ET-1
G5665T polymorphism alters the potentiation response of
human internal thoracic artery rings to exogenous ET-1.
The ET-1 G5665T genotype did not alter direct contraction
to exogenous ET-1 at concentrations of greater than 100
pmol/L, but at subthreshold concentrations, arteries from
patients with the G/T and T/T genotypes contracted more
vigorously to low concentrations of phenylephrine than did
those from patients with the G/G genotype, suggesting that
this polymorphism either alters vascular reactivity directly
or is in linkage disequilibrium with another mutation that
does so.
The results of the current study demonstrate that the ET-1
G5665T mutation is associated with a significant decrease in
transplant-free survival for palliated single-ventricle patients
(P 5 .002), with the majority of the decrement occurring in
patients with HLHS (P 5 .0002). It is important to note
that in this patient population HLHS was not a risk factor2008
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(Figure 3), but patients with HLHS seem to be preferentially
vulnerable to the effects of this SNP. Whether this implies
a higher sensitivity of patients with HLHS to increased vas-
cular reactivity or another mechanism of action cannot be de-
termined based on these data alone. Although the functional
effect of this SNP has not been delineated, these data support
the general supposition that afterload reduction might be use-
Figure 2. Transplant-free actuarial survival for patients with hypo-
plastic left heart syndrome (A; n 5 64, P 5 .0002) or other single-
ventricle anatomy (B; n 5 101, P 5 .1) stratified by endothelin-1
G5665T polymorphism genotype. ET1, Enothelin-1.The Journal of Thorful for long-term therapy of single-ventricle patients, particu-
larly those with HLHS. It is also important to note that these
data demonstrate an association between this polymorphism
and outcome, but causality is only implied. These results
would be entirely consistent with this SNP serving as
a marker for another functionally significant mutation in link-
age disequilibrium.
In our study the effects of the T allele did not appear to be
additive because the T/T group had significantly worse mid-
term transplant-free survival than the other groups, but the G/
T heterozygotes were not significantly different from the G/G
homozygotes. This pattern is most consistent with a recessive
gene model in which the poor T phenotype is only expressed
in T homozygotes. Interestingly, this pattern was also demon-
strated by Tiret and associates8 in their study of the effects of
this same SNP on hypertension and obesity in adults. In that
study the G/G and G/T subgroups had comparable blood
pressures, whereas the T/T subgroup had significantly higher
systolic and diastolic blood pressures.
Our data must be considered within the limitations of the
study design. Although many of the patients (n5 111) were
enrolled prospectively as they presented to our institution for
staged palliation, this study also included patients who were
born and palliated in the past. For this older patient subgroup,
the limitations of a retrospective study might apply. This
Figure 3. Transplant-free actuarial survival for single-ventricle
patients stratified by cardiac diagnosis: hypoplastic left heart syn-
drome (HLHS; n 5 64) versus other single-ventricle anatomy (n 5
101). P 5 .76.acic and Cardiovascular Surgery c Volume 136, Number 1 121
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opposing selection biases. On the one hand, there is a poten-
tial bias toward inclusion of longer-term survivors simply
because those patients are still alive and available for enroll-
ment. On the other hand, this group includes a large number
of previously transplanted (or ‘‘failed’’) single-ventricle pal-
liations (n 5 24), and because the follow-up for patients un-
dergoing transplantation is far more meticulous than for other
patient groups, resulting in fewer patients lost to follow-up,
there is a potential opposite bias toward better enrollment
of early failures. Finally, although the subgroup analyses
were interesting and suggestive, the number of patients
within the anatomic subgroups was relatively small, and
therefore further patient enrollment and follow-up will be
necessary to increase statistical power before definitive state-
ments can be made regarding the interaction between anat-
omy and genotype.
In conclusion, this study demonstrates that genetic factors
can play a role in the long-term outcome of palliated single-
ventricle patients. Further studies are needed to confirm these
findings in larger patient populations, as well as to evaluate
the role of other candidate gene mutations. Given the rela-
tively low incidence of the ET-1 5665 T/T genotype, a multi-
center study would be required for any potential therapeutic
trial of endothelin blockade in this apparently higher-risk
group.122 The Journal of Thoracic and Cardiovascular Surgery c JulyReferences
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